Liminatus Pharma, Inc. (Nasdaq: LIMN) has announced that it has successfully regained compliance with Nasdaq’s minimum bid price requirements, according to a Form 8-K filed with the Securities and Exchange Commission.
On January 15, 2026, the company received a notice from Nasdaq indicating that its common stock had closed below $1.00 per share for 30 consecutive business days. This non-compliance triggered a transfer of listing from The Nasdaq Global Market to The Nasdaq Capital Market, effective August 4, 2026. The company was granted an extension to demonstrate compliance with Nasdaq Listing Rule 5550(a)(2) by September 3, 2026.
To address the price issue, Liminatus effected a 1-for-50 reverse stock split at the close of trading on August 20, 2026. Following this adjustment, the company received a notice from Nasdaq on September 24, 2026, confirming that the closing bid price of its common stock had remained above $1.00 per share for 13 consecutive trading days from August 21, 2026, to September 9, 2026.
Consequently, Nasdaq determined that the company has met the requirements of the Bid Price Rule, and the matter has been closed. The company issued a press release on September 29, 2026, to announce this determination.
